Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors

References

• Writing G, Edaravone A. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
   PubMed Web of Science ®Google Scholar
• Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta. 2015;1852:679–84.
   PubMed Web of Science ®Google Scholar
• van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610–e23.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• Riancho J, Bosque-Varela P, Perez-Pereda S, Povedano M, de Munain AL, Santurtun A. The increasing importance of environmental conditions in amyotrophic lateral sclerosis. Int J Biometeorol. 2018;62:1361–74.
   PubMed Web of Science ®Google Scholar
• Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002;13:311–9.
   PubMed Web of Science ®Google Scholar
• Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, et al. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis. 2005;2:195–201.
   PubMed Web of Science ®Google Scholar
• Fang F, Peters TL, Beard JD, Umbach DM, Keller J, Mariosa D, et al. Blood lead, bone turnover, and survival in amyotrophic lateral sclerosis. Am J Epidemiol. 2017;186:1057–64.
   PubMed Web of Science ®Google Scholar
• Malek AM, Barchowsky A, Bowser R, Heiman-Patterson T, Lacomis D, Rana S, et al. Environmental and occupational risk factors for amyotrophic lateral sclerosis: a case-control study. Neurodegener Dis. 2014;14:31–8.
   PubMed Web of Science ®Google Scholar
• Filippini T, Tesauro M, Fiore M, Malagoli C, Consonni M, Violi F, et al. Environmental and occupational risk factors of amyotrophic lateral sclerosis: a population-based case-control study. Int J Environ Res Public Health. 2020;17:2882.
   PubMed Web of Science ®Google Scholar
• Meng E, Mao Y, Yao Q, Han X, Li X, Zhang K, et al. Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2020;41:35–40.
   PubMed Web of Science ®Google Scholar
• Gunnarsson LG, Bodin L. Amyotrophic lateral sclerosis and occupational exposures: a systematic literature review and meta-analyses. Int J Environ Res Public Health. 2018;15:2371.
   PubMed Web of Science ®Google Scholar
• Riancho J, Sanchez de la Torre JR, Paz-Fajardo L, Limia C, Santurtun A, Cifra M, et al. The role of magnetic fields in neurodegenerative diseases. Int J Biometeorol. 2021;65:107–17.
   PubMed Web of Science ®Google Scholar
• Luna J, Leleu JP, Preux PM, Corcia P, Couratier P, Marin B, et al. Residential exposure to ultra high frequency electromagnetic fields emitted by Global System for Mobile (GSM) antennas and amyotrophic lateral sclerosis incidence: a geo-epidemiological population-based study. Environ Res. 2019;176:108525.
   PubMed Web of Science ®Google Scholar
• Vinceti M, Malagoli C, Fabbi S, Kheifets L, Violi F, Poli M, et al. Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:583–9.
   PubMed Web of Science ®Google Scholar
• Peters S, Visser AE, D’Ovidio F, Beghi E, Chio A, Logroscino G, et al. Associations of electric shock and extremely low-frequency magnetic field exposure with the risk of amyotrophic lateral sclerosis. Am J Epidemiol. 2019;188:796–805.
   PubMedGoogle Scholar
• D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509–27.
   PubMed Web of Science ®Google Scholar
• Chetty CS, Vemuri MC, Campbell K, Suresh C. Lead-induced cell death of human neuroblastoma cells involves GSH deprivation. Cell Mol Biol Lett. 2005;10:413–23.
   PubMed Web of Science ®Google Scholar
• Qian Y, Zheng Y, Ramos KS, Tiffany-Castiglioni E. The involvement of copper transporter in lead-induced oxidative stress in astroglia. Neurochem Res. 2005;30:429–38.
   PubMed Web of Science ®Google Scholar
• Fowler BA, Whittaker MH, Lipsky M, Wang G, Chen XQ. Oxidative stress induced by lead, cadmium and arsenic mixtures: 30-day, 90-day, and 180-day drinking water studies in rats: an overview. Biometals. 2004;17:567–8.
   PubMed Web of Science ®Google Scholar
• Prasanthi RP, Devi CB, Basha DC, Reddy NS, Reddy GR. Calcium and zinc supplementation protects lead (Pb)-induced perturbations in antioxidant enzymes and lipid peroxidation in developing mouse brain. Int J Dev Neurosci. 2010;28:161–7.
   PubMed Web of Science ®Google Scholar
• Ahamed M, Siddiqui MK. Low level lead exposure and oxidative stress: current opinions. Clin Chim Acta. 2007;383:57–64.
   PubMed Web of Science ®Google Scholar
• Shadnia S, Azizi E, Hosseini R, Khoei S, Fouladdel S, Pajoumand A, et al. Evaluation of oxidative stress and genotoxicity in organophosphorus insecticide formulators. Hum Exp Toxicol. 2005;24:439–45.
   PubMed Web of Science ®Google Scholar
• Franco R, Sanchez-Olea R, Reyes-Reyes EM, Panayiotidis MI. Environmental toxicity, oxidative stress and apoptosis: menage a trois. Mutat Res. 2009;674:3–22.
   PubMed Web of Science ®Google Scholar
• Schmuck G, Rohrdanz E, Tran-Thi QH, Kahl R, Schluter G. Oxidative stress in rat cortical neurons and astrocytes induced by paraquat in vitro. Neurotox Res. 2002;4:1–13.
   PubMed Web of Science ®Google Scholar
• Muniz JF, McCauley L, Scherer J, Lasarev M, Koshy M, Kow YW, et al. Biomarkers of oxidative stress and DNA damage in agricultural workers: a pilot study. Toxicol Appl Pharmacol. 2008;227:97–107.
   PubMed Web of Science ®Google Scholar
• Mbah Ntepe LJ, Habib R, Judith LN, Raza S, Nepovimova E, Kuca K, et al. Oxidative stress and analysis of selected SNPs of ACHE (rs 2571598), BCHE (rs 3495), CAT (rs 7943316), SIRT1 (rs 10823108), GSTP1 (rs 1695), and Gene GSTM1, GSTT1 in chronic organophosphates exposed groups from Cameroon and Pakistan. Int J Mol Sci. 2020;21:6432.
   Web of Science ®Google Scholar
• Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci. 2017;44:90–5.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9:177–83.
   PubMed Web of Science ®Google Scholar
• Simpson EP, Yen AA, Appel SH. Oxidative stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol. 2003;15:730–6.
   PubMed Web of Science ®Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241–5.
   PubMed Web of Science ®Google Scholar
• Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry. 2014;85:1232–8.
   PubMed Web of Science ®Google Scholar
• Factor-Litvak P, Al-Chalabi A, Ascherio A, Bradley W, Chio A, Garruto R, et al. Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14: 33–43.
   PubMed Web of Science ®Google Scholar
• Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2010–2011. MMWR Suppl. 2014;63:1–14.
   PubMedGoogle Scholar
• Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, et al. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:192–203.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Goetz R, Factor-Litvak P, Hupf J, McElhiney M, Singleton J, et al. Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:265–73.
   PubMed Web of Science ®Google Scholar
• Rabkin J, Goetz R, Murphy JM, Factor-Litvak P, Mitsumoto H, Group ACS. Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort. Neurology. 2016;87:1320–8.
   PubMed Web of Science ®Google Scholar
• Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, et al. Association between dietary intake and function in amyotrophic lateral sclerosis. JAMA Neurol. 2016;73:1425–32.
   PubMed Web of Science ®Google Scholar
• Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 2016;86:813–20.
   PubMed Web of Science ®Google Scholar
• Horton DK, Graham S, Punjani R, Wilt G, Kaye W, Maginnis K, et al. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:126–33.
   PubMed Web of Science ®Google Scholar
• Nelson LM, Tanner CM, Van Den Eeden S, McGuire VM, editors. Neuroepidemiology. From principles to practice. New York, NY: Oxford University Press; 2004.
   Google Scholar
• Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol. 1992;135:1029–41.
   PubMed Web of Science ®Google Scholar
• Ann DH. The occupational environment: its evaluation, control, and management. Falls Church, VA: American Industrial Hygiene Association Press; 2014.
   Google Scholar
• Louis ED, Jurewicz EC, Applegate L, Factor-Litvak P, Parides M, Andrews L, et al. Association between essential tremor and blood lead concentration. Environ Health Perspect. 2003;111:1707–11.
   PubMed Web of Science ®Google Scholar
• Bowman JD, Touchstone JA, Yost MG. A population-based job exposure matrix for power-frequency magnetic fields. J Occup Environ Hyg. 2007;4:715–28.
   PubMed Web of Science ®Google Scholar
• Pearce N. Analysis of matched case-control studies. BMJ. 2016;352:i969.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, Seals RM, Webster TF. Bias amplification in epidemiologic analysis of exposure to mixtures. Environ Health Perspect. 2018;126:047003.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. New York, NY: Oxford University Press; 1998:18–33.
   Google Scholar
• Mitsumoto H, Garofalo DC, Santella RM, Sorenson EJ, Oskarsson B, Fernandes JAM, Jr, et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:263–72.
   PubMed Web of Science ®Google Scholar
• Loikkanen J, Naarala J, Vahakangas KH, Savolainen KM. Glutamate increases toxicity of inorganic lead in GT1-7 neurons: partial protection induced by flunarizine. Arch Toxicol. 2003;77:663–71.
   PubMed Web of Science ®Google Scholar
• Kriscenski-Perry E, Durham HD, Sheu SS, Figlewicz DA. Synergistic effects of low level stressors in an oxidative damage model of spinal motor neuron degeneration. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:151–7.
   PubMed Web of Science ®Google Scholar
• Sahin E., Gümüşlü S. Alterations in brain antioxidant status, protein oxidation and lipid peroxidation in response to different stress models. Behav Brain Res. 2004;155:241–8.
   PubMed Web of Science ®Google Scholar
• Quandt SA, Jones BT, Talton JW, Whalley LE, Galvan L, Vallejos QM, et al. Heavy metals exposures among Mexican farmworkers in eastern North Carolina. Environ Res. 2010;110:83–8.
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:9–18.
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;112:649–60.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
   PubMed Web of Science ®Google Scholar
• Hupf JFL, Goetz R, et al. ARREST ALS: an extension of the ALS COSMOS study. Amyotroph Lateral Scler Frontotemporal Degener. 2018;176–7.
   Google Scholar
• Beard JD, Steege AL, Ju J, Lu J, Luckhaupt SE, Schubauer-Berigan MK. Mortality from amyotrophic lateral sclerosis and Parkinson’s disease among different occupation groups – United States, 1985–2011. MMWR Morb Mortal Wkly Rep. 2017;66:718–22.
   PubMed Web of Science ®Google Scholar